Dr Thomas Powles from Barts Cancer Institute, London, UK, talks to ecancer with several leading renal oncologists at ECC 2013 held in Amsterdam between 27 September to 1 October 2013. 

Focusing on highlights from the congress, the experts share their views of the latest real-world data with pazopanib.  Dr. Matrana gives an overview of the 2-year results from MD Anderson presented at the meeting and Dr. Galvis outlines the real-world Christie Manchester, UK, experience with pazopanib.  Both confirmed that pazopanib was as effective and well-tolerated as it has been in the clinical trial setting, and they discuss their results.  Observed toxicity in the real-world setting is also discussed, including how to manage hypertension and transaminitis in clinical practice, and the possibility of drug interactions.

Finally, the panel comment on the use of pazopanib in the first-line setting.

This programme has been supported by a grant from GlaxoSmithKline.